01 — At a Glance
The Pharmacy Unicorn That Bleeds Money
- 52-Week High / Low₹1,740 / ₹752
- Q3FY26 Revenue₹142.95 Cr
- Q3FY26 PAT-₹29.5 Cr
- Q3FY26 EPS-₹8.73
- Davaindia Stores2,331
- Book Value₹93.5
- Price to Book12.4x
- Dividend Yield0.09%
- Debt / Equity0.57x
- QIP Raised (Dec 2025)₹350 Cr
The Real Story: Zota posted ₹1,430 crore in Q3FY26 revenue (up 98% YoY), lost ₹295 crore in the quarter, and raised ₹350 crore via QIP because the math doesn’t work yet. Welcome to the “we’ll be profitable later” economy, where 2,331 stores matter more than actual profits. The stock crashed 29.5% in 6 months because turns out, investors eventually care about money you actually make.
02 — Introduction
The Pharmacy Chain That’s Growing Faster Than Common Sense
Zota Health Care is India’s answer to the question: “What if we opened pharmacy stores so fast that profits become a luxury we can’t afford right now, but trust us, bro, we have a five-year plan.”
The company operates Davaindia, a retail pharmacy chain that sells generic medicines at 30–90% discounts compared to branded equivalents. Simple idea. Scalable model. Asset-light franchisee structure (893 FOFO stores out of 2,331). And a management team that’s willing to torch quarterly profits in the temple of national expansion with evangelical zeal.
In Q3FY26, Zota opened 276 stores in a single quarter. That’s 2.9 stores per day. 365 days a year, no weekends. The company hit a market cap of ₹3,949 crore despite negative ROCE (-17%), negative ROE (-36%), and a consolidated PAT of -₹72.7 crore for the full year ending Mar 2025. Investors are either genius speculators or madly in love with the narrative. Possibly both.
The Feb 2026 concall revealed something fascinating: Zota is consciously deprioritizing near-term profitability to maximize store velocity and distribution footprint. CEO (virtually) said: “If we stop opening stores, we hit 15–17% EBITDA by FY28–29.” Translation: you’re not buying a profitable business; you’re buying a land-grab story in the pharmacy retail space. And land grabs require cash. Lots of it.
Feb 2026 Concall Gold: “Over 500 stores being put into process… not a run-rate scenario.” Management literally admitted Q3 was abnormal. Then told investors that normalizing headcount in the next 1–2 quarters would bring employee costs down. Music to ears that like pain-then-gain narratives.
03 — Business Model: WTF Do They Actually Do?
Three Vertical Acts: Domestic Drugs, Davaindia Stores, and Exports
Zota has morphed from a traditional pharma exporter into a retail pharmacy operator with a weird three-ring circus: (1) domestic distribution of generic drugs through 1,050+ distributors, (2) Davaindia retail stores (the money-burning part everyone focuses on), and (3) exports to 30+ countries (the boring stable cash generator).
Davaindia is the show. Started in 2015 with a simple thesis: Indian patients overpay for branded meds. A ₹1,000 box of branded amoxicillin can be had as a generic for ₹150. Davaindia positioned itself as the Costco of medicines—buy generic, save big, don’t ask questions.
The model is asset-light: 38% COCO (Company-Owned Company-Operated), 62% FOFO (Franchise-Owned Franchise-Operated). FOFO stores don’t hit the balance sheet hard—franchisees bear capex; Zota earns supply margin + franchise fees. But growth required cash: hire pharmacists, train them, secure licenses, manage working capital. Cue ₹350 crore QIP in December 2025.
The concall revealed the real lever: gross margins are already 66–67%, with management targeting 70% over 4–6 quarters. Mature COCO stores hit 25–30% EBITDA. Mature FOFO stores (franchisee-side) hit 40–45%, but Zota captures only the supply margin portion. This is classic retail math: skinny per-unit margins, massive volume, and leverage at scale. The only problem? Scale is still destroying consolidated profitability.
Revenue MixDavaindia 80%Q3FY26
Store Growth+276In Q3 Alone
Target by Mar 20295,000Davaindia Stores
The Dirty Truth: 2,331 stores with 49 lakh quarterly footfall (19.5 lakh per month = ~8.5k footfall/month/store). Mature stores do 80–100 customers/day. New stores do 15–20. The company is opening stores at breakeven-to-loss in year 1, betting on year 2–3 maturity. This math works IF the stores actually mature profitably AND if working capital doesn’t explode. Right now, both are uncertain.
💬 Real talk: Are you visiting Davaindia pharmacies near you? Or are branded medicines still winning in your neighborhood?
04 — Financials Overview
Q3 FY26: The Quarterly Snapshot
Result type: Quarterly Results | Q3 FY26 EPS: ₹-8.73 | Annualised EPS (Q3×4): ₹-34.92 | Full-year FY25 EPS: ₹-19.70
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 142.95 | 72.17 | 129.42 | +98.2% | +10.5% |
| Operating Profit | -0.38 | -6.21 | 6.08 | +93.9% | -106.2% |
| OPM % | -0% | -9% | 5% | +900 bps | -500 bps |
| PAT | -29.5 | -19.07 | -15.83 | -54.7% | -86.4% |
| EPS (₹) | -8.73 | -6.78 | -5.20 | -28.8% | -67.9% |
Ouch Department: Revenue is exploding (+98% YoY), but PAT is imploding (-55% QoQ). The concall explained this: 231 COCO stores opened in Q3, plus ~400+ more in the pipeline, all with staffing/training costs fully loaded in the quarter. Employee costs ballooned from ₹38 crore (Q2) to ₹52 crore (Q3). Management says this is temporary—normalizing to ₹38–40 crore range by next quarter as the intake pipeline slows. Spoiler: investors were not convinced, and the stock tanked.
05 — Valuation: Is This a Bargain or a Trap?
Three Valuation Methods Walk Into a Bar…
Method 1: P/S (Price-to-Sales) Based
TTM Sales = ₹473 Cr. CMP ₹1,159 × 34.1 Cr shares = Market Cap ₹3,949 Cr. P/S = 3,949 / 473 = 8.35x. Sector median P/S for pharma retail = 2–3x. Zota is trading at 3–4x sector median.
Fair Range (P/S 2–4x): ₹280 – ₹560
Method 2: EV/Revenue Based
Enterprise Value = ₹4,124 Cr (Mkt Cap ₹3,949 + Net Debt ₹175 Cr). EV/Revenue = 8.7x. Quality growth retail/pharma names trade at 3–5x EV/Revenue when profitable. Zota is unprofitable, so discount that range.
EV/Revenue (2.5x–4.5x for profitable comps): ₹237 Cr – ₹425 Cr → Per share:
Range: ₹280 – ₹475
Method 3: DCF (The Hopium Version)
Assume Zota reaches 5,000 stores by Mar 2029 (target). Assume mature store base delivers 15% EBITDA by then. Conservative: ₹500–600 Cr EBITDA by FY29. Using 5-year forward view with 12% WACC:
→ Current cash burn: ₹50–60 Cr/quarter (assume moderates to ₹20–30 Cr by FY28)
→ Cumulative burn FY26–28: ~₹150–200 Cr
→ FY29 onwards: profitable, modest free cash flow
→ Terminal value (8% cap rate, ₹550 Cr EBITDA): ~₹6,875 Cr
→ Discount back 4 years at 12%: ~₹4,365 Cr
→ Less: burns to date & working capital needs: ~₹400–500 Cr
→ Implied equity value: ~₹3,800–3,900 Cr
Range: ₹300 – ₹550
Fair Min: ₹280
CMP: ₹1,159 | Fair Max: ₹560
Overvalued
⚠️ EduInvesting Fair Value Range: ₹280 – ₹560. CMP ₹1,159 is 2–4x above even optimistic DCF scenarios. This valuation depends entirely on: (1) store maturity acceleration, (2) gross margin expansion to 70%, (3) EBITDA reaching 15%+ by FY28, and (4) no major execution slip-ups. This fair value range is for educational purposes only and is not investment advice.
06 — What’s Cooking: News, Triggers & Drama
The Pharmacy Wars Are Getting Spicy
